Limits...
Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression.

Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR - Int J Gen Med (2011)

Bottom Line: DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4.In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration.DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Molecular Pharmacology.

ABSTRACT

Background: DLBS3233 is a standardized extract combination containing Lagerstroemia speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin secretion, and insulin signaling was examined in this study.

Methods: 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene expression detected using the reverse transcription polymerase chain reaction method. Immunoblotting assay and in vitro glucose uptake assay were also carried out in the experiment.

Results: DLBS3233 was seen to increase phosphorylation at the tyrosine residue of the insulin receptor substrate. DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4. In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration. The combination of extracts also increased glucose uptake and adiponectin secretion, and decreased resistin secretion significantly relative to control cells. Moreover, DLBS3233 administered to insulin-resistant Wistar rats showed an ability to control blood sugar, insulin levels, and other lipoproteins, including high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol.

Conclusion: DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

No MeSH data available.


Related in: MedlinePlus

Peroxisome proliferator-activated receptor gamma gene expression after administration of Cinnamomum burmanii extract (A), Lagestroemia speciosa extract (B), and DLBS3233 (C) at various concentrations.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108202&req=5

f2-ijgm-4-345: Peroxisome proliferator-activated receptor gamma gene expression after administration of Cinnamomum burmanii extract (A), Lagestroemia speciosa extract (B), and DLBS3233 (C) at various concentrations.

Mentions: In order to confirm the activity of DLBS3233 as a combination compared with each plant it is derived from, the effects of C. burmanii and L. speciosa on PPARγ gene expression were studied individually. It can be seen in Figures 2A and 2B that neither C. burmanii nor L. speciosa had any significant effect on PPARγ gene expression when used alone. The level of gene expression appeared to be similar after administration of both these plants compared with controls. These data suggest that, when used in combination, C. burmanii and L. speciosa interact with each other, causing the native characteristics of each extract to work synergistically to strengthen their pharmacological activity.


Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression.

Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR - Int J Gen Med (2011)

Peroxisome proliferator-activated receptor gamma gene expression after administration of Cinnamomum burmanii extract (A), Lagestroemia speciosa extract (B), and DLBS3233 (C) at various concentrations.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108202&req=5

f2-ijgm-4-345: Peroxisome proliferator-activated receptor gamma gene expression after administration of Cinnamomum burmanii extract (A), Lagestroemia speciosa extract (B), and DLBS3233 (C) at various concentrations.
Mentions: In order to confirm the activity of DLBS3233 as a combination compared with each plant it is derived from, the effects of C. burmanii and L. speciosa on PPARγ gene expression were studied individually. It can be seen in Figures 2A and 2B that neither C. burmanii nor L. speciosa had any significant effect on PPARγ gene expression when used alone. The level of gene expression appeared to be similar after administration of both these plants compared with controls. These data suggest that, when used in combination, C. burmanii and L. speciosa interact with each other, causing the native characteristics of each extract to work synergistically to strengthen their pharmacological activity.

Bottom Line: DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4.In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration.DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Molecular Pharmacology.

ABSTRACT

Background: DLBS3233 is a standardized extract combination containing Lagerstroemia speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin secretion, and insulin signaling was examined in this study.

Methods: 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene expression detected using the reverse transcription polymerase chain reaction method. Immunoblotting assay and in vitro glucose uptake assay were also carried out in the experiment.

Results: DLBS3233 was seen to increase phosphorylation at the tyrosine residue of the insulin receptor substrate. DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4. In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration. The combination of extracts also increased glucose uptake and adiponectin secretion, and decreased resistin secretion significantly relative to control cells. Moreover, DLBS3233 administered to insulin-resistant Wistar rats showed an ability to control blood sugar, insulin levels, and other lipoproteins, including high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol.

Conclusion: DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

No MeSH data available.


Related in: MedlinePlus